• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by SCYNEXIS Inc. (Amendment)

    4/3/23 8:11:16 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCYX alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

    Amendment No. 4

     

    Under the Securities Exchange Act of 1934

     

      SCYNEXIS, INC.  
      (Name of Issuer)  
         
     

    Common Stock

     
      (Title of Class of Securities)  
         
      811292101  
      (CUSIP Number)  
         
      March 22, 2023  
      (Date of Event Which Requires Filing of this Statement)  
         

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed

     

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 811292101   

     

    1.

    Names of Reporting Persons. AIGH Capital Management, LLC

    I.R.S. Identification Nos. of above persons (entities only).

     

    27-4413262

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    Maryland

    Number of Shares

    Beneficially

    Owned by Each

    Reporting 

    Person

    With

     

    5.

    Sole Voting Power

     

     1,159,346

    6.

    Shared Voting Power

     

    0

    7. 

    Sole Dispositive Power 

     

    1,159,346

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,159,346

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    3.5%

    12.

    Type of Reporting Person (See Instructions)

     

    OO

      

     

     

     

    CUSIP No.  811292101   

     

    1.

    Names of Reporting Persons. Orin Hirschman

    I.R.S. Identification Nos. of above persons (entities only).

     

     

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐

    (b) ☒

    3.

    SEC Use Only

     

    4.

    Citizenship of Place of Organization

     

    United States

    Number of Shares

    Beneficially

    Owned by Each

    Reporting

    Person

    With

    5.

    Sole Voting Power

     

    1,159,346

    6.

    Shared Voting Power

     

    7. 

    Sole Dispositive Power 

     

    1,159,346

    8.

    Shared Dispositive Power

     

     

    9.

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,159,346

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares ☐

     

     

    11.

    Percent of Class Represented by Amount in Row 9

     

    3.5%

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

     

     

     

    ITEM 1:

     

    (a) Name of Issuer:

     

    SCYNEXIS, INC.

     

    (b) Address of Issuer’s Principal Executive Offices:

     

    1 Evertrust Plaza, 13th Floor

    Jersey City NJ 07302

     

    ITEM 2:

     

    (a) Name of Person Filing:

     

    This Schedule 13G is being jointly filed by each of the following persons pursuant to Rule 13d-1 promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended (the “Act”):

     

      (i)   AIGH Capital Management, LLC, a Maryland limited liability company (“AIGH LP”), as an Advisor or Sub-Advisor with respect to shares of Common Stock (as defined in Item 2(d) below) held by AIGH Investment Partners, L.P. and WVP Emerging Manger Onshore Fund, LLC;
           
      (ii)   AIGH Investment Partners, L.L.C., a Delaware limited liability company (“AIGH LLC”), with respect to shares of Common Stock (as defined in Item 2(d) below) directly held by it;
           
      (iii)   Mr. Orin Hirschman (“Mr. Hirschman”), who is the Managing Member of AIGH Capital Management, LLC and president of AIGH LLC, with respect to shares of Common Stock indirectly held by AIGH LP, directly by AIGH LLC and Mr. Hirschman and his family directly.

     

    AIGH Capital Management LLC., AIGH Investment Partners LLC, and Mr. Hirschman are hereinafter sometimes collectively referred to as the “Reporting Persons.” Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    (b) Address of Principal Business Office or, if None, Residence:

     

    The principal office and business address of AIGH Investment Partners, L.P., AIGH Investment Partners LLC, and Mr. Hirschman is:

     

    6006 Berkeley Avenue

    Baltimore MD 21209

     

    (c) Citizenship:

     

    See Item 2(a) above and Item 4 of each cover page.

     

    (d) Title of Class of Securities:

     

    Common Stock

     

    (e) CUSIP Number:

     

    811292101

     

     

     

     

    ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO §§240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
           
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
           
      (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
           
      (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
           
      (e) ☒ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
      (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
      (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
      (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
      (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j) ☐ A non-U.S. institution, in accordance with §240.13d-1(b)(1)(ii)(J);
           
      (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K).
         

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________.

     

    ITEM 4: OWNERSHIP.

     

    See Item s 5,6,7,8 and 9 of each cover page.

     

    ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒

     

    ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.

     

    Not applicable.

     

    ITEM 7: IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.

     

    Not applicable.

     

    ITEM 8: IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.

     

    Not applicable.

     

    ITEM 9: NOTICE OF DISSOLUTION OF GROUP.

     

    Not applicable.

     

    ITEM 10: CERTIFICATIONS.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: April 3, 2023 By: /s/ Orin Hirschman
        Orin Hirschman,
        Individually and as (a) managing member of AIGH Capital Management LLC.:  and (b) president of AIGH Investment Partners LLC.

     

     

     

    Get the next $SCYX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCYX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCYX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

    JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting data on the Company's second-generation fungerp drug candidate, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI), which is taking place from January 28 to 30, 2026, in Las Vegas, Nevada. "We are pleased to participate in this important inaugural multidisciplinary meeting focused on addressing the significant threat of antimicrobial resistance," said David Angulo, M.D., Presi

    1/28/26 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247

    The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration ("FDA") has granted the Company Qualified Infectious Disease Product (QIDP) and Fast Track Designations for its second-generation triterpenoid antifungal therapy, SCY-247. "Receiving FDA's QIDP

    1/21/26 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

    JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market ("Nasdaq") to regain compliance with the minimum bid price requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). The Company now has until June 15, 2026, to meet the requirement for its shares of common stock to maintain a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days. Nasdaq granted the extension after determining that SC

    12/22/25 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    1/8/26 8:19:28 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/25 2:27:47 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by SCYNEXIS Inc.

    SCHEDULE 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/12/25 1:09:48 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (ORIG-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 11:20:46 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

    Submission status for SCYNEXIS, INC's drug BREXAFEMME (SUPPL-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

    6/2/21 9:57:42 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Macleod Ivor was granted 129,833 shares, increasing direct ownership by 48% to 398,529 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:03:14 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Sukenick Scott was granted 129,833 shares, increasing direct ownership by 29% to 574,539 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:02:11 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Angulo Gonzalez David was granted 391,333 shares, increasing direct ownership by 46% to 1,244,431 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    2/2/26 4:01:08 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aegis Capital reiterated coverage on SCYNEXIS with a new price target

    Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $35.00 from $40.00 previously

    6/7/21 9:58:05 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aegis Capital reiterated coverage on SCYNEXIS with a new price target

    Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $40.00 from $45.00 previously

    4/12/21 12:54:40 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group reiterated coverage on SCYNEXIS with a new price target

    Maxim Group reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $22.00 from $17.00 previously

    2/17/21 2:23:39 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

    4 - SCYNEXIS INC (0001178253) (Issuer)

    9/16/24 8:00:27 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/24 7:07:26 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/6/24 8:56:32 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    10/7/24 1:38:20 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Financials

    Live finance-specific insights

    View All

    GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

    Brexafemme complements GSK's industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royaltiesSCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assetsSCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today LONDON and JERSEY CITY, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- GSK plc (NYSE:GSK) and SCYNEXIS, Inc. (NASDAQ:SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (i

    3/30/23 7:05:00 AM ET
    $GSK
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer.Marco Taglietti, M.D., to retire as President and Chief Executive Officer of SCYNEXIS and step down from the Board of Directors on December 31, 2022. David Angulo, M.D., Chief Medical Officer of SCYNEXIS will become President and Chief Executive Officer and join the Board effective January 1, 2023.BREXAFEMME® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3

    11/9/22 7:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

    JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022. Conference call and webcast details: Investors (domestic): (844) 826-3033Investors (international): (412) 317-5185Webcast:  LinkConference ID: 10172836 A live audio webcast can be accessed by visiting the Investor Relations section of the Company'

    11/1/22 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCYX
    Leadership Updates

    Live Leadership Updates

    View All

    AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

    Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICSDr Perros becomes Chairman of the Board These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization Lyon (France), Thursday July 24, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce th

    7/24/23 8:00:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

    Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLsAppointed Christine Coyne as Chief Commercial Officer to lead the launch of ibrexafungerp (Brexafemme®) for the treatment of vaginal yeast infections, following expected approval by June 1st Began dosing patients in a Phase 1 trial of the IV formulation of ibrexafungerpFurther strengthened balance sheet and projected cash runway into 2023 JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology c

    5/17/21 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

    Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal p

    5/11/21 8:30:00 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care